Additionally, the increased probability of death shortly after TB treatment coupled with the known risk of TB recurrence associated with low CD4 [26] underscore the need for clinics and programs to strengthen the coverage and uptake of intermittent preventive therapy in TB survivors. This evidence concerns the gene CD4 and tuberculosis.